A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

ABSTRACT: This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors likely to exhibit elevated levels of Epidermal Growth Factor Receptor (EGFR).

DISEASE(S): Colorectal Carcinoma,Squamous Cell Carcinoma Of Head And Neck,Glioblastoma Multiforme,Carcinoma,Triple Negative Breast Neoplasms,Glioblastoma,Non-small Cell Lung Cancer,Colorectal Neoplasms,Triple Negative Breast Cancer,Head And Neck Squamous Cell Carcinoma,Solid Tumors,Cancer

PROVIDER: 2184006 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR